Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Receivables - Accured (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Receivables - Accured for 5 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • Quarterly Receivables - Accured rose 18.52% to $6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, up 18.52% year-over-year, with the annual reading at $6.4 million for FY2025, 18.52% up from the prior year.
  • Receivables - Accured for Q4 2025 was $6.4 million at Janux Therapeutics, up from $6.3 million in the prior quarter.
  • The five-year high for Receivables - Accured was $28.0 million in Q3 2021, with the low at $3000.0 in Q2 2021.
  • Average Receivables - Accured over 5 years is $4.1 million, with a median of $2.2 million recorded in 2023.
  • Peak annual rise in Receivables - Accured hit 9900.0% in 2022, while the deepest fall reached 98.93% in 2022.
  • Over 5 years, Receivables - Accured stood at $200000.0 in 2021, then surged by 250.0% to $700000.0 in 2022, then skyrocketed by 214.29% to $2.2 million in 2023, then skyrocketed by 145.45% to $5.4 million in 2024, then grew by 18.52% to $6.4 million in 2025.
  • According to Business Quant data, Receivables - Accured over the past three periods came in at $6.4 million, $6.3 million, and $5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.